ZNTL Stock Quote Price and Forecast | CNN

ZNTL

Zentalis Pharmaceuticals, Inc.

Key terms

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in New York, NY.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Key terms

Smart score

Today 6:27am ET Buy Rating on Zentalis Pharmaceuticals: Strategic Developments and Multi-Cancer Treatment Potential of Azenosertib by TipRanks Yesterday 7:07am ET Zentalis announces anticipated upcoming milestones by TipRanks Yesterday 7:05am ET Zentalis sees cash runway into mid-2026 by TipRanks Yesterday 7:05am ET Zentalis reports Q1 EPS 14c, consensus (77c) by TipRanks Apr 09 4:43pm ET Zentalis Pharmaceuticals to Present at Upcoming Conferences by TipRanks Apr 01 7:59am ET Immunome price target raised to $33 from $27 at Wedbush by TipRanks Mar 01 1:04am ET Zentalis Pharmaceuticals: A Cautious Hold Amidst Speculative Opportunities and Upcoming Clinical Updates by TipRanks Feb 29 5:19pm ET Zentalis files automatic mixed securities shelf by TipRanks Feb 28 8:48am ET Zentalis price target raised to $15 from $12 at Wedbush by TipRanks Feb 28 7:47am ET Oppenheimer Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL) by TipRanks Feb 28 6:38am ET Buy Rating Affirmed for Zentalis Pharmaceuticals on Strategic Positioning and Clinical Prospects in Ovarian Cancer Treatment by TipRanks Feb 28 5:43am ET Buy Rating on Zentalis Pharmaceuticals Amidst Undervalued Share Price and Promising Clinical Developments by TipRanks Feb 27 1:25pm ET TD Cowen Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL) by TipRanks Feb 27 7:06am ET Zentalis sees cash runway into 2026 by TipRanks Feb 27 7:05am ET Zentalis announces anticipated upcoming milestones by TipRanks Feb 27 7:03am ET Zentalis reports 2023 EPS ($4.47), consensus ($4.54) by TipRanks Feb 15 4:22pm ET Zentalis Pharmaceuticals Updates Bylaws for Enhanced Governance by TipRanks

May 03 10:48am ET Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm by Newsfile

1-year income & revenue

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Scaffolding and construction netting near an apartment building in New York, US, on Wednesday, Oct. 11, 2023. Monthly fees and expenses for inspections, insurance and climate-friendly upgrades are squeezing residents of the city's many co-op and condo buildings. Photographer: Michael Nagle/Bloomberg

Michael Nagle/Bloomberg/Getty Images

For US renters, the chance of owning a home is going from bad to worse

Close-up detail of the Disney+ app icon on an Apple iPhone 12 Pro smartphone screen, on November 11, 2020. (Photo by Phil Barker/Future Publishing via Getty Images)

Phil Barker/Future Publishing/Getty Images

Disney just had its worst day in a year and a half

People shop in a supermarket in the Manhattan borough of New York city on January 27, 2024. (Photo by Charly TRIBALLEAU / AFP) (Photo by CHARLY TRIBALLEAU/AFP via Getty Images)

Charly Triballeau/AFP/Getty Images

Americans have spent their savings. Economists worry about what comes next

Berkshire Hathaway Chairman Warren Buffett walks through the exhibit hall as shareholders gather to hear from the billionaire investor at Berkshire Hathaway Inc's annual shareholder meeting in Omaha, Nebraska, on May 4, 2019.

Scott Morgan/Reuters/File

Warren Buffett compares AI to nuclear weapons in stark warning